Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 5Recruiting 5Not yet recruiting 5Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 12Gastrointestinal 8Tumor-Agnostic 3Head & Neck 3Breast 3Gynecologic 2CNS 2Sarcoma 1Other solid neoplasm 1Endocrine 1

Conditions

Nasopharyngeal Carcinoma 2Thyroid Neoplasms 1Recurrence 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × anlotinib × Head & Neck × Clear all
NCT04996758 2024-12-12

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Sun Yat-sen University

Phase 2 Completed
40 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06367010 2024-04-16

Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients

Jiangxi Provincial Cancer Hospital

Completed
8 enrolled
Head & Neck

Thyroid Neoplasms

NCT03906058 2023-10-25

Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy

Sun Yat-sen University

Phase 2 Completed
39 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡